Movement Alert｜Recursion Pharmaceuticals, Inc. Intraday Decline 7.52%, market reassesses REC-4881 registrational path after prior data-driven rally

Market Focus11-12 23:00

On November 12, Recursion Pharmaceuticals, Inc. fell 7.52% in Regular Trading, trading at $3.3801 per share, with turnover of $20.4921 million.

The clearest catalyst cited in recent market updates is a reassessment of REC-4881 after the prior session’s data-driven advance, with investors shifting from the initial positive reaction to evaluating the program’s registrational trial path and the scope for valuation recovery.

Recent company disclosures showed updated Phase 2 data for REC-4881 in familial adenomatous polyposis indicating meaningful reductions in polyp burden and a relatively clean safety profile that supports a planned registrational study. Separately, Recursion Pharmaceuticals, Inc. reported quarterly revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22, and the company also appointed pharma veteran Fred Hassan as chair of the board.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment